A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-05161704 After Administration Of Single Escalating Oral Doses Under Fed And Fasted Conditions In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2010
At a glance
- Drugs PF 5161704 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 23 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2010 New trial record